ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -49 مورد

Limited-stage diffuse large B cell lymphoma: Response-guided management

Limited-stage diffuse large B cell lymphoma: Response-guided management
This algorithm describes initial management of limited-stage (stage I or II) DLBCL. Refer to related UpToDate material for details of diagnosis and staging of DLBCL, PET response scoring, administration of R-CHOP and RT, and post-treatment assessment and monitoring.

DLBCL: diffuse large B cell lymphoma; PET: positron emission tomography; R-CHOP: rituximab, cyclophosphamide, vincristine, doxorubicin, prednisone; R-pola-CHP: rituximab, polatuzumab, cyclophosphamide, doxorubicin, prednisone; RT: radiation therapy.

* Some experts favor R-pola-CHP for bulky disease or for adverse prognostic features; if R-pola-CHP is selected, it should replace R-CHOP throughout this algorithm. Refer to related UpToDate material for details of adverse prognostic features and R-pola-CHP administration.

¶ If biopsy is negative, administer RT to involved site with boost to PET-avid sites. If biopsy is positive, treat as refractory DLBCL, as discussed in related UpToDate material.

Δ Either approach is acceptable, with choice guided by distribution of PET activity, comorbidities, and patient preference, as discussed in related UpToDate material.

◊ If biopsy is negative, treat with 3 additional cycles of R-CHOP. If biopsy is positive, treat as refractory DLBCL, as discussed in related UpToDate material.
Graphic 145363 Version 1.0